The latest news from academia, regulators
research labs and other things of interest
Posted: January 21, 2008
BioAlliance Pharma Publishes Its 2008 Financial Calendar and Announces the Opening of Its European Corporate Headquarters
(Nanowerk News) BioAlliance Pharma SA (PARIS:BIO) (Euronext Paris - ticker code BIO) has announced its financial calendar for 2008, which notably includes the publication dates for its revenue statements and half-year & annual accounts, as well as the date of its shareholders' Annual General Meeting:
January 31 2008 : Publication of the revenue statement for Q4 2007
February 29 2008 : Publication of the consolidated accounts for 2007. SFAF analyst meeting at the Palais Brongniart
April 11 2008 : Publication of the French "Document de Reference" for 2007
April 29 2008 : Annual General Meeting at the Maison de la Chimie
April 30 2008 : Publication of the revenue statement for Q1 2008
July 21 2008 : Publication of the revenue statement for Q2 2008
August 28 2008 : Publication of the consolidated half-year accounts as of June 30 2008. SFAF analyst meeting at the Maison de la Chimie
October 30 2008 : Publication of the revenue statement for Q3 2008
January 2009 : Publication of the revenue statement for Q4 2008
Along with other corporate information on BioAlliance Pharma S.A., a regularly updated "investor relations" section is available on the company's website (www.bioalliancepharma.com).
Furthermore, in Q1 2008, BioAlliance Pharma will present its corporate communication program for shareholders and the financial community as a whole.
BioAlliance Pharma expands and is set to open its European corporate headquarters.
BioAlliance Pharma will move into new premises in February 2008.
The new corporate headquarters (located at 49, boulevard du General Martial Valin, in Paris' 15th Arrondissement - just down the street from its current offices) will more than double the available floor space and will enable the company to bring together its entire staff onto a single site.
"The opening of our European corporate HQ represents another important milestone and testifies to our commitment to pursuing growth whilst keeping costs under control. We are going to boost our international performance levels, notably by integrating our Development, Regulatory Affairs and Sales & Marketing teams. This is a strategic choice for progressing our product portfolio, at a time when Loramyc® is being launched on the French market and has already been granted marketing approval in other European countries, in line with our stated objectives", commented Dominique Costantini, CEO.
About BioAlliance Pharma
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.
In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).